Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
Other Sizes |
|
ln Vitro |
In cynomolgus monkey and human samples, nemvaleukin alfa activates lymphocyte subsets with EC50s ranging from 0.45 to 2.2 nM[2]. On human cells (HH cells), nemvaleukin alfa (0-100 nM, 30 minutes) causes the activation of medium-affinity IL-2R [3]. With an EC50 of 0.45 nM, nemvaleukin alfa (0-100 nM, 30 minutes) activates pSTAT5 in NK cells [3]. Effector cells derived from human peripheral blood get activated in response to 0.5 nM nemvaleukin alfa administered over a 5-day period [3].
|
---|---|
ln Vivo |
Mice's SCLC tumor growth is inhibited by nemvaleukin alfa (6 mg/kg, subcutaneous injection, once every 4 days)[1].
|
Animal Protocol |
Animal/Disease Models: SCLC orthotopic model[1]
Doses: 6 mg/kg Route of Administration: sc, every 4 days Experimental Results: Delayed tumor growth and prolonged survival. Animal/Disease Models: Male cynomolgus monkeys (PK Assay)[2] Doses: 0.3 or 1 mg /kg Route of Administration: iv or sc Experimental Results: pharmacokinetic/PK profile of Nemvaleukin alfa. Dose Route dose (mg/kg) Cmax (ng/mL) Tmax (h) T1/2 (h) iv 0.3 6119 0.083 49.5 sc 0.3 549 8 61.9 sc 1 1035 8 37.3 |
References |
[1]. Pan Y, et al, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer. J Immunother Cancer. 2022 Sep;10(9):e004913.
[2]. Lopes JE, et al. Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys. J Pharmacol Exp Ther. 2021 Nov;379(2):203-210. [3]. Lopes JE, et al. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 Apr;8(1):e000673. |
CAS # |
2315268-27-8
|
---|---|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.